Breaking News

BONESUPPORT Appoints Chief Medical Officer

By PR Newswire | April 11, 2017

Michael Diefenbeck M.D., Ph.D. founded Scientific Consulting in Orthopaedic Surgery in 2014.

BONESUPPORT AB, a developer of injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces the appointment of Michael Diefenbeck M.D., Ph.D. as chief medical officer.
Dr. Diefenbeck founded Scientific Consulting in Orthopaedic Surgery in 2014 and has worked for BONESUPPORT on a range of clinical projects related to CERAMENT as an independent clinical advisor.
He is currently honorary consultant at Nuffield Orthopaedic Centre, Oxford University Hospitals. Dr. Diefenbeck studied medicine at Munich and was trained as an orthopedic surgeon, specializing in trauma care and bone infections. He has 14 years' clinical experience at different German hospitals (BG Unfallklinik Murnau, BG Kliniken Bergmannstrost Halle/Saale, University Hospital Jena and Schön Klinik Hamburg Eilbek). At University Hospital Jena he finished his Ph.D. in 2011 and has since been involved in surgical education and training programs for students. He is author of 24 Pub-med listed research articles.
Dr. Diefenbeck said: "I am excited to be joining BONESUPPORT at a particularly exciting time for the company. I look forward to working with the BONESUPPORT team, to help shape the future development of the company as it continues to develop and reinforce the clinical benefits that its CERAMENT based products deliver."
Richard Davies, CEO of BONESUPPORT, said: "We are pleased to welcome Michael to the BONESUPPORT team. I have no doubt that his extensive medical experience in the orthopedics field and his knowledge of our CERAMENT platform that he will be a real asset to BONESUPPORT as we look to grow our business and deliver value to all of our stakeholders."
Dr. Diefenbeck began his new role in April 2017 and reports to the CEO.